Compare CBAN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAN | RLMD |
|---|---|---|
| Founded | 1975 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.6M | 461.9M |
| IPO Year | 1995 | 2012 |
| Metric | CBAN | RLMD |
|---|---|---|
| Price | $20.31 | $3.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $25.13 | $10.75 |
| AVG Volume (30 Days) | 114.7K | ★ 1.3M |
| Earning Date | 10-21-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | 16.91 | ★ 45.28 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $27.95 | N/A |
| Revenue Next Year | $34.25 | N/A |
| P/E Ratio | $22.31 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $15.80 | $1.80 |
| 52 Week High | $22.46 | $8.00 |
| Indicator | CBAN | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 22.55 |
| Support Level | $20.03 | N/A |
| Resistance Level | $20.40 | $4.44 |
| Average True Range (ATR) | 0.46 | 0.19 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 43.42 | 9.83 |
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.